



CSD/BSE&NSE/PR/2024-2025
October 3, 2024

To
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai – 400001

To
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400051

Scrip Code: 530239

Scrip Symbol: SUVEN

Dear Sir/Madam,

Sub: News Release

.....
With reference to above subject, please find enclosed News Release of our company titled
**“Suven Life Sciences to Present Positive Results from Phase-2a Proof-of-Concept Study of
Ropanicant (SUVN-911) and Updates on Innovation Pipeline Assets at Neuroscience 2024,
Chicago, USA”**

This is for your information and record.

Thanking You,
Yours faithfully,
For **Suven Life Sciences Limited**

Shrenik Soni
Company Secretary

Encl: as above

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor | Road No.5
Avenue 7 | Banjara Hills | Hyderabad – 500034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: +91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com

News Release

Suven Life Sciences to Present Positive Results from Phase-2a Proof-of-Concept Study of Ropanicant (SUVN-911) and Updates on Innovation Pipeline Assets at Neuroscience 2024, Chicago, USA.

The scientific session scheduled at Neuroscience 2024 will provide the comprehensive findings from the Phase-2a proof-of-concept signal detection open label study of Ropanicant.

Suven plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025.

Join us at exhibit booth # 1666 at Neuroscience 2024 to learn about the latest advancements in Suven Innovation pipeline.

Hyderabad, India (3-Oct-2024): Suven Life Sciences Ltd (Suven) announces five presentations covering clinical and pre-clinical assets from their portfolio of new chemical entities at the upcoming Neuroscience 2024 conference, taking place during October 5-9, 2024, in Chicago, Illinois, USA. Neuroscience 2024, the annual meeting of the Society for Neuroscience (SfN), will bring together neuroscientists from around the globe, representing leading Pharma, Biotech and Clinical Research institutes.

Presentation Titles:

- Ropanicant (SUVN-911), an $\alpha 4\beta 2$ nAChR Antagonist: A Phase-2 Study Evaluating the Safety and Efficacy in Participants with Moderate to Severe Major Depressive Disorder.
- Samelisant (SUVN-G3031): Safety and Efficacy Outcome from the Phase-2 Proof-of-Concept, Double-Blind, Placebo-Controlled Study in Patients with Narcolepsy.
- Rationale and Study Design for the Phase-3 Clinical Development Program of Masupirdine (SUVN-502), a Pure 5-HT₆ Receptor Antagonist, for the Treatment of Agitation in Patients with Dementia of Alzheimer's Type.
- Dual 5-HT_{1A} and 5-HT_{2A} Receptor Ligand SUVN-2206043 shows Antipsychotic and Antidepressant Like Effects in Animal Models.
- SUVN-L3307032, a Positive Allosteric Modulator (PAM) at Muscarinic M₄ Receptor for the Treatment of Psychotic Symptoms.

Suven is showcasing its Innovation Pipeline and comprehensive summaries at Neuroscience 2024 at exhibit booth # 1666.

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor | Road No.5
Avenue 7 | Banjara Hills | Hyderabad – 500034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: +91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com



About Suven Life Sciences (“Suven”): Suven Life Sciences Limited (Suven) is focused on the discovery and clinical development of innovative medicines that address unmet medical needs in central nervous system (CNS) disorders. We have portfolio of advanced stage clinical candidates and research programs that are designed for CNS disorders such as Alzheimer’s disease (AD), sleep disorders, major depressive disorders (MDD), Parkinson’s disease (PD), Schizophrenia, Pain disorders, and Gastrointestinal disorders. Suven has 7 clinical stage assets across focus areas: Masupirdine (SUVN-502) for the treatment of agitation in patients with dementia of the Alzheimer's type (Phase-3 study ongoing); Samelisant (SUVN-G3031) for excessive daytime sleepiness (EDS) in narcolepsy (Phase-2 study completed; pivotal Phase-3 study in planning); Ropanicant (SUVN-911) for MDD (Open-label Phase-2a study completed; Placebo-controlled Phase-2b study in planning); Usmarapride (SUVN-D4010) for cognitive disorders (Phase-2 study in planning), SUVN-I6107 for cognitive disorders (Phase-1 study initiated) and 2 other compounds in early stages of clinical development. In addition to these clinical assets, we have 6 projects in research pipeline across multiple potential indications. Suven owns all intellectual property rights for its assets in all major markets.

For more information, please visit our website <http://www.suven.com>

Risk Statement: *Except for historical information, all the statements, expectations, and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve several risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances, and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.*

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor | Road No.5
Avenue 7 | Banjara Hills | Hyderabad – 500034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: +91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com